Reduction of myocardial infarct size remains an important objective in reperfusion therapy. Timely mechanical or pharmacological reperfusion is essential, but beyond that, acute therapies to reduce infarct size and limit reperfusion injury are largely lacking. Erythropoietin had been demonstrated to reduce infarct size in experimental models, although the data are somewhat mixed.1-8 Therefore, it would seem to be a logical agent to test prospectively in a trial of acute myocardial infarction (MI).9
Bhatt DL. Evaluation of Agents to Reduce Infarct SizeIt Can Be Quite REVEALing. JAMA. 2011;305(18):1908–1909. doi:10.1001/jama.2011.600
Customize your JAMA Network experience by selecting one or more topics from the list below.